do glp 1 agonists cause pancreatic cancer Risk of associated with GLP-1 receptor agonist therapy Updates in Medicine | GLP-1s

doi: 10.1210/jc.2016-3285 24 WalzerDTurcuAFJhaSAbelBSAuchusRJMerkeDPet al

When one drug inhibits CYP enzymes responsible for metabolising another CNS drug, plasma and brain concentrations may rise, increasing the risk of toxicity

L., Ng, C

Preliminary results indicate that such drugs might not only be effective for obesity and diabetes but also for a number of other diseases including osteoarthritis, Parkinson's disease and a range of conditions caused by a buildup of fat in the liver, known as nonalcoholic steatohepatitis (NASH) (Brandt, Mller, DiMarchi)

The FDA approval of Wegovy pill is based on the results from the OASIS 4 Phase 3 clinical trial, which was a 64-week medical study that included 307 adults with obesity or overweight with one or more weight-related comorbidities, without diabetes

70 We already highlighted some limitations of the present study, that is, the limited sample size and study duration